Literature DB >> 24681704

Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.

Lisa M Baumann Kreuziger1, Yvonne H Datta, Andrew D Johnson, Nicole D Zantek, Ryan Shanley, Mark T Reding.   

Abstract

The international normalized ratio (INR) can be unreliable in patients with lupus anticoagulants (LACs) or other conditions affecting baseline testing. Alternative methods to assess anticoagulation on warfarin through measures of vitamin K-dependent factor activity by clot based or chromogenic assays may be necessary. In this patient population, the ideal method is unknown. Thirty-six patients stable on warfarin with LAC or unreliable INR testing had an INR, a prothrombin time-based clotting assay for factor II (FII) activity, and a chromogenic assay for factor X (CFX) activity were performed simultaneously. Eighty-nine sets of measurements were obtained of which 83 sets included all three assays. CFX and FII levels were well correlated (r = 0.92) in all patients and in 26 patients with a documented antiphospholipid antibody (r = 0.93). Parallel testing was seen in 99% of FII assays. Sixty-one percent of CFX and 57% of FII were within the therapeutic range. In 32 CFX and FII pairs wherein assessment of anticoagulation was discordant, 16 CFX agreed with INR and 13 FII agreed with INR (McNemar's, χ = 0.14, P = 0.7). The number of times tests were discrepant was not statistically different between CFX and FII (P = 0.36). CFX and FII activity are well correlated in patients that require alternative monitoring of warfarin. Either test can be used in this population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24681704      PMCID: PMC4350672          DOI: 10.1097/MBC.0000000000000030

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  15 in total

1.  Anti-prothrombin antibodies and the lupus anticoagulant.

Authors:  R A Fleck; S I Rapaport; L V Rao
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

2.  Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.

Authors:  S E Lind; P W Callas; E A Golden; K A Joyner; T L Ortel
Journal:  Blood Coagul Fibrinolysis       Date:  1997-01       Impact factor: 1.276

3.  Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.

Authors:  A Tripodi; V Chantarangkul; M Clerici; B Negri; M Galli; P M Mannucci
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

4.  Monitoring warfarin therapy in patients with lupus anticoagulants.

Authors:  S Moll; T L Ortel
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

5.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe Méthodologie en Hémostase du Groupe d'Etudes sur l'Hémostases et la Thrombose.

Authors:  A Robert; A Le Querrec; B Delahousse; C Caron; L Houbouyan; B Boutière; M H Horellou; G Reber; P Sié
Journal:  Thromb Haemost       Date:  1998-07       Impact factor: 5.249

7.  Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients.

Authors:  M H Horellou; M H Aurousseau; M C Boffa; J Conrad; M L Wiesel; M Samama
Journal:  J Med       Date:  1987

8.  Assessment of the validity of the INR system for patients with liver impairment.

Authors:  M J Kovacs; A Wong; K MacKinnon; K Weir; M Keeney; E Boyle; M Cruickshank
Journal:  Thromb Haemost       Date:  1994-06       Impact factor: 5.249

9.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

Review 10.  Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis.

Authors:  Kathleen J Pincus; Asha L Tata; Kristin Watson
Journal:  Ann Pharmacother       Date:  2012-05-08       Impact factor: 3.154

View more
  2 in total

1.  Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report.

Authors:  Rocio Bautista Sanchez; Yumiko Gely; Josune Natalia Iglesias
Journal:  J Med Cases       Date:  2022-04-23

2.  Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.

Authors:  Ravi Sarode; Katsuyuki Fukutake; Masahiro Yasaka; Michael A Tortorici; Antoinette Mangione; Marc Pfister; Adam Cuker
Journal:  Blood Adv       Date:  2020-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.